Chammas & Marcheteau advised Xelya and the sellers in the framework of the OBO. Goodwin and MB Avocats advised Parquest. The founders of Xelya, together with...
Xelya’s OBO
Shift4Good’s Launch of Shift4Good Fund 1 SLP
Chammas & Marcheteau and CNPLaw LLP advised Shift4Good SAS on the deal. CNP also advised Hera Capital Partners Pte Ltd. Singapore and France-based venture capital fund...
Diabeloop’s Series C Fundraising
McDermott Will & Emery advised Diabeloop on the deal. Chammas & Marcheteau advised LBO France. Diabeloop, a Grenoble-based artificial intelligence company specialising in the treatment of...
Domain Therapeutics’ €38 Million Fundraising
Chammas & Marcheteau advised Turenne Capital on the deal while Bird & Bird represented Domain Therapeutics. Jones Day advised CTI Life Sciences Fund, Panacea Venture, and...
Domain Therapeutics’ €39 Million Fundraising
Chammas & Marcheteau advised Turenne Capital on the deal. Lavery de Billy and Bird & Bird represented Domain Therapeutics. Jones Day advised CTI Life Sciences Fund,...
Maltem’s Acquisition of Esokia
IN BRIEF: Chammas & Marcheteau, advised on the matter. Chammas & Marcheteau advised Maltem Consulting Group with a team including J??e Chapron (Corporate M&A), Denis Marcheteau...
Andera Partners’ Closing of Andera Smart Infra 1
IN BRIEF: Chammas & Marcheteau, advised on the matter. Chammas & Marcheteau advised Andera Partners with a team including Christophe Moreau (Picture – Tax M&A and...
Azulis Capital’s Investment in Phocéenne de Cosmétique
IN BRIEF: Chammas & Marcheteau, Hoche Société d’Avocats, advised on the matter. Chammas & Marcheteau advised Azulis Capital, BNP Paribas with a team including Christophe Moreau...
Xerfi’s €30 Million Financing Round
IN BRIEF: Chammas & Marcheteau, Mazars, Vivien & Associés, advised on the matter. Chammas & Marcheteau advised NextStage AM, Sopromec Participations with a team including St?hanie...